logo

DYN

Dyne·NASDAQ
--
--(--)
--
--(--)
2.75 / 10
Underperform

Fundamental analysis shows Dyne Therapeutics in a weak position (2.8/10). Key positives include Profit-MV and Cash-MV, but negatives such as Net profit / Total profit (%) and Revenue-MV drag the score down. Historical back-tests indicate modest one-month returns (e.g., 7.79% for Profit-MV) yet low confidence, underscoring the fragility of the fundamentals.

Fundamental(2.75)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-0.26
Score1/3
Weight10.92%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight9.60%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-0.84%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight16.35%
1M Return7.79%
PB-ROE
Value0.60
Score0/3
Weight7.46%
1M Return3.56%
Current assets turnover ratio
Value1.78
Score2/3
Weight1.91%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.39%
1M Return0.86%
Asset-MV
Value-0.50
Score2/3
Weight37.31%
1M Return15.13%
Cash-MV
Value-0.07
Score2/3
Weight16.37%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.48%
1M Return-0.30%
Is DYN undervalued or overvalued?
  • DYN scores 2.75/10 on fundamentals and holds a Premium valuation at present. Backed by its -50.58% ROE, 0.00% net margin, -6.58 P/E ratio, 3.93 P/B ratio, and -1.12% earnings growth, these metrics solidify its Underperform investment rating.